DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.

Saved in:
Bibliographic Details
Main Authors DAVID, Olivier, DUMORTIER, Thomas, SCHMOUDER, Robert, LOOBY, Michael
Format Patent
LanguageEnglish
Published 12.05.2022
Subjects
ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
AbstractList S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
Author DAVID, Olivier
LOOBY, Michael
SCHMOUDER, Robert
DUMORTIER, Thomas
Author_xml – fullname: DAVID, Olivier
– fullname: DUMORTIER, Thomas
– fullname: SCHMOUDER, Robert
– fullname: LOOBY, Michael
BookMark eNrjYmDJy89L5WTQdPEPdnR3VQhydff0dfVTcPMPUnBUCDYMAIo4uwaEgLju_n6ewSE8DKxpiTnFqbxQmptB2c01xNlDN7UgPz61uCAxOTUvtSQ-NNjIwMjI0MTI0sTS0dCYOFUAhTMmtw
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID US2022142949A1
GroupedDBID EVB
ID FETCH-epo_espacenet_US2022142949A13
IEDL.DBID EVB
IngestDate Fri Jul 19 10:43:21 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US2022142949A13
Notes Application Number: US202117479649
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220512&DB=EPODOC&CC=US&NR=2022142949A1
ParticipantIDs epo_espacenet_US2022142949A1
PublicationCentury 2000
PublicationDate 20220512
PublicationDateYYYYMMDD 2022-05-12
PublicationDate_xml – month: 05
  year: 2022
  text: 20220512
  day: 12
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies Novartis AG
RelatedCompanies_xml – name: Novartis AG
Score 3.387565
Snippet S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the...
SourceID epo
SourceType Open Access Repository
SubjectTerms ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220512&DB=EPODOC&locale=&CC=US&NR=2022142949A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp-LHlIJS8KFItzRLH4psabpNWFvWVvY21i4FQeZwFf99L6HTPe0tyUG-4PLL5e53AXi0uzld5IRaCKfSIsxxLZcRZsmSMLqUCOiljvIN6SgjrzNn1oCPLRdG5wn90ckRUaMK1PdKn9fr_0csX8dWbp7zd2z6fAlSzzdr61ixRu2O6Q88EUd-xE3OvSwxw6mW2Xj2ErePttKBukirTPvibaB4KetdUAlO4TDG_lbVGTTkqgXHfPv3WguOJrXLG4u19m3O4cmPlAPImIrheCJCAw04o28kdowtXMSpqg6jcJykF_AQiJSPLBxz_rfEeZbsTrB7CU00_uWVolQvlqRkZeHKglBasAIhpycLp9Mrc7wtXEN7X083-8W3cKKqyhtud9rQrL6-5R2CbJXf6735BT-peqk
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5KFetNq2K1akAJeAiSdJMmhyBtHk20edAk0lto0g0IUouN-PedXVLtqbfdGdgXzH4zO48FeJAHhbYoiCYhnFKJ6KohGTrRJVoRXVtSBPSKR_mGmpeRl7k6b8HHNheG1wn94cURUaJKlPea39fr_0csm8dWbp6KdyR9PrupaYuNdcyyRmVFtMemE0d2ZImWZWaJGM44T8a7lxgjtJUOhqw-L1Oe3sYsL2W9CyruCRzGON6qPoUWXXWhY23_XuvCUdC4vLHZSN_mDB7tiDmAhJkz8QMnFNCAE0ZCIsdIsZw4Zd1JFPpJeg73rpNanoRz5n9bzLNkd4GDC2ij8U8vWUr1YkkqvSoNWhJNK_USIWdIS1UZVgVqCz3o7xvpaj_7DjpeGkzzqR--XsMxYzHPuKz0oV1_fdMbBNy6uOXn9AskcH2W
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=DOSAGE+REGIMEN+FOR+A+S1P+RECEPTOR+AGONIST&rft.inventor=DAVID%2C+Olivier&rft.inventor=DUMORTIER%2C+Thomas&rft.inventor=SCHMOUDER%2C+Robert&rft.inventor=LOOBY%2C+Michael&rft.date=2022-05-12&rft.externalDBID=A1&rft.externalDocID=US2022142949A1